Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]
Pre-clinicalUNKNOWN 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatitis C in Substance Users
Conditions
Hepatitis C in Substance Users
Trial Timeline
Nov 15, 2022 → May 15, 2024
NCT ID
NCT05503979About Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]
Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa] is a pre-clinical stage product being developed by Gilead Sciences for Hepatitis C in Substance Users. The current trial status is unknown. This product is registered under clinical trial identifier NCT05503979. Target conditions include Hepatitis C in Substance Users.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05503979 | Pre-clinical | UNKNOWN |
Competing Products
20 competing products in Hepatitis C in Substance Users
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK2809 + Placebos | Viking Therapeutics | Phase 2 | 47 |
| TERN-501 + TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-201 | Terns Pharmaceuticals | Phase 1 | 30 |
| IVA337 + IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo + Empagliflozin | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo | Inventiva | Phase 3 | 72 |
| Pegasys® + Pegasys® | Chugai Pharmaceutical | Approved | 85 |
| peginterferon alfa-2a + rivavirin | Chugai Pharmaceutical | Phase 3 | 77 |
| SOF + COPE | Chugai Pharmaceutical | Pre-clinical | 23 |
| Colesevelam Hcl | Daiichi Sankyo | Phase 2 | 52 |
| ASP9831 + Placebo | Astellas Pharma | Phase 2 | 52 |
| FK788 | Astellas Pharma | Phase 2 | 52 |
| MK-2248 | Merck | Phase 1 | 33 |
| Interferon alfacon-1 | Astellas Pharma | Phase 3 | 77 |
| Pegylated Interferon + Ribavirin | Astellas Pharma | Approved | 85 |
| Tacrolimus + steroids, monoclonal anti-IL2R antibody | Astellas Pharma | Phase 2 | 52 |
| Dolutegravir + Rlipivirine + GSK1265744 | Shionogi | Phase 1 | 33 |
| Dolutegravir + Methadone | Shionogi | Phase 1 | 33 |
| Clevudine + Adefovir | Eisai | Phase 3 | 77 |